Personal and health care giant Johnson & Johnson has announced plans to acquire privately-held Aragon Pharmaceuticals in a deal that could reach $1 billion, according to reports. The acquisition is a strategic move for Johnson & Johnson into the market for pharmaceutical drugs that specialize in fighting diseases caused and driven by hormones. Reports say the deal between the parties includes a $650 million payment upfront as well as payments of $350 million in increments as the company reaches certain milestones. Aragon will reportedly separate the rest of its assets into a new business. Aragon is currently in the mid-stage of development of a drug to fight prostate cancer. The deal is expected to close in the third quarter of the year.
Full Content: Fox Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI